Collaborating with govt agencies to develop treatment for COVID-19: Cipla

The Mumbai-based drug firm is also ramping up manufacturing of essential drugs required in the fight against the pandemic, company's chairman YK Hamied said.

published on : 5th August 2020

Cipla all set to launch Favipiravir drug for treatment of COVID patients: CSIR

An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild, moderate cases

published on : 23rd July 2020

COVID-19: Cipla launches generic version of remdesivir in India, looking to supply over 80,000 vials within first month

Cipla had earlier said the drug will be priced at less than Rs 5,000 per 100 mg vial in line with its overall philosophy of driving access and affordability.

published on : 9th July 2020

Two Indian firms up Remdesivir production

Cipla and Hetero, the two Indian pharma majors, under licence from  Gilead  Sciences,  have started manufacturing  Remdisivir after DCGI approved it in June for Covid-19 patients.

published on : 5th July 2020

Cipla shares gain over 3 percent as company launches generic remdesivir for COVID-19 patients

It rose 2.94 per cent to close at Rs 655.80 on the BSE. During the day, it jumped 9.24 per cent to a one-year high of Rs 696. On the National Stock Exchange (NSE), it gained 3.10 per cent to close at

published on : 22nd June 2020

Cipla launches generic remdesivir for COVID-19 patients in India

The USFDA had issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc for emergency use of remdesivir for the treatment of COVID-19 patients.

published on : 21st June 2020

Four Indian firms ink licensing pact with Gilead for COVID-19 drug Remdesivir

The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat COVID-19 patients.

published on : 14th May 2020

IICT transfers Favipiravir production process to Cipla

The Hyderabad-based Indian Institute of Chemical Technology (IICT) has developed a convenient and cost-effective synthetic process for producing antiviral drug Favipiravir.

published on : 2nd May 2020

Cipla, CSIR, IICT to develop up a drug to fight the coronavirus?

Cipla would look after trials, approvals, and mass production of the drugs.

published on : 18th March 2020

Cipla gets US FDA warning letter over Goa facility

The Mumbai-based firm also said it remains committed to maintain highest standards of compliance and will work closely with FDA to comprehensively address all the observations.

published on : 27th February 2020

Cipla picks up 4 key brands from Wanbury for up to Rs 89 crore

The move is expected to increase Cipla’s market presence in the large women’s health segment, with all four brands largely sold to women in order to treat nutritional deficiencies.

published on : 9th February 2020